Related Experiment Videos
A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy
1Department of Radiation Oncology, University of Liverpool, Clatterbridge Hospital, Wirral, Merseyside, UK.
Abstract:
The identification of activated oncogenes as the basic biochemical difference between tumour cells and normal cells has opened up the possibility for development of truly tumour specific chemotherapy. It may be hypothesized that malignant cells would revert to a more normal phenotype and might even be triggered into terminal differentiation if expression of the appropriate oncogenes were inhibited. Although, at present, it is not possible to anticipate what form future therapy based upon this approach would take, it is clear that the immediate priority must be to establish the general validity of the hypothesis with a variety of tumour cell types in vitro. For this purpose antisense oligonucleotide analogues appear to offer considerable promise as sequence specific inhibitors of oncogene expression. However, no analogue structure yet devised fulfils all the requirements of an ideal antisense effector in terms of biological stability, cell uptake, non-toxicity, hybridization efficiency and mechanism of action on target nucleic acids. Inhibition of oncogene expression in certain cell types has been reported using antisense oligonucleotides but the technique is not universally applicable and more detailed biochemical investigations of the interactions of oligonucleotides with intact cells are required before improved structures may be developed.
Insights
Targeting activated oncogenes offers a novel approach to cancer chemotherapy. Inhibiting oncogene expression may revert malignant cells to a normal state, but challenges remain in developing effective antisense oligonucleotide analogues for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Activated oncogenes represent a key biochemical difference between tumor and normal cells.
- This difference presents an opportunity for developing targeted cancer therapies.
- The hypothesis suggests inhibiting oncogene expression could induce differentiation or reversion to a normal phenotype in malignant cells.
Purpose of the Study:
- To investigate the general validity of inhibiting oncogene expression in various tumor cell types in vitro.
- To explore the potential of antisense oligonucleotide analogues as sequence-specific inhibitors of oncogene expression.
- To identify the limitations and requirements for ideal antisense effectors in cancer therapy.
Main Methods:
- Utilizing antisense oligonucleotide analogues as tools to inhibit oncogene expression.
- Conducting in vitro studies on a variety of tumor cell types.
- Biochemical investigations into the interactions of oligonucleotides with intact cells.
Main Results:
- Antisense oligonucleotide analogues show promise for sequence-specific inhibition of oncogene expression.
- Successful inhibition of oncogene expression has been reported in certain cell types.
- Current antisense analogue structures have limitations regarding stability, cell uptake, toxicity, and efficacy.
Conclusions:
- Inhibiting oncogene expression is a promising strategy for tumor-specific chemotherapy.
- Further research is needed to develop improved antisense oligonucleotide structures.
- Detailed biochemical studies are required to overcome current limitations for universal applicability.